(19)
(11) EP 0 977 562 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.04.2006 Bulletin 2006/17

(45) Mention of the grant of the patent:
04.01.2006 Bulletin 2006/01

(21) Application number: 99909941.9

(22) Date of filing: 10.03.1999
(51) International Patent Classification (IPC): 
A61K 31/335(2006.01)
 A61K 47/22(2006.01)
(86) International application number:
PCT/US1999/005151
(87) International publication number:
WO 1999/045918 (16.09.1999 Gazette 1999/37)

(54)

METHODS AND COMPOSITIONS FOR DELIVERY OF TAXANES

VERFAHREN UND ZUSAMMENSETZUNGEN ZUR VERABREICHUNG VON TAXANEN

METHODES ET COMPOSITIONS D'ADMINISTRATION DE TAXANES

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 10.03.1998 US 77459 P

(43) Date of publication of application:
09.02.2000 Bulletin 2000/06

(73) Proprietor: Tapestry Pharmaceuticals, Inc.
Boulder, CO 80301 (US)

(72) Inventor:
  • McCHESNEY-HARRIS, Lisa, L.
    Vernon Hills, IL 60061-1317 (US)

(74) Representative: Lawrence, Malcolm Graham et al
HLBBshaw Merlin House Falconry Court Baker's Lane
Epping, Essex CM16 5DQ
Epping, Essex CM16 5DQ (GB)


(56) References cited: : 
WO-A-95/11039
 WO-A-98/30205
   
  • CHANG T ET AL: "THE EFFECT OF WATER-SOLUBLE VITAMIN E (TPGS) ON ORAL CYCLOSPORINE PHARMACOKINETICS IN HEALTHY VOLUNTEERS" CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 57, no. 1, 1 January 1995, XP000196224
  • ADAMS M.W.: "d-alpha Tocopheryl Polyethylene Glycol 1000 Succinate (Eastman Vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds" CONGR. INT. TECHNOL. PHARM./6TH, vol. 4, 1992, pages 254-262, XP002011712
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).